Author: Ken Dropiewski

NorthStar Medical Radioisotopes Expands Business Platform with New, Patient-focused, Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) Services Unit

− Complements NorthStar’s growing radioisotope production programs, providing powerhouse combination of capabilities and expertise to advance patient care – − Full-scale CDMO services for collaborating companies designed to facilitate radiopharmaceutical development and commercialization in complex, highly regulated radiopharmaceutical sector – − NorthStar to be the first and only U.S. company […]

CytoSorbents Announces Pivotal STAR-T Trial Reaches First Milestone With 40 Patients Enrolled

PRINCETON, N.J., Nov. 14, 2022  /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that 40 of the targeted 120 patients have been enrolled in the Safe and Timely Antithrombotic Removal – Ticagrelor (STAR-T) trial, achieving the […]

Renibus Therapeutics Raises $33 Million Bridge Financing to Advance its Portfolio of Cardiorenal Product Candidates

SOUTHLAKE, Texas, Nov. 14, 2022 /PRNewswire/ — Renibus Therapeutics, Inc., (“Renibus”), a clinical-stage biotechnology company developing breakthrough products for cardiorenal diseases, today announced a $33 million bridge financing consisting of a $23 million SAFE (Simple Agreement for Future Equity) offering and $10 million pursuant to the first tranche of a $30 million term loan with Oxford Finance LLC (“Oxford”). The […]

VentureMed FLEX Vessel Prep™ System 12-Month Data To Be Presented at VEITH Symposium 2022 in PAD with DCB’s and AV Access Management

MINNEAPOLIS, Nov. 14, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced new data presentations in peripheral artery disease (PAD) with DCB’s in addition to 12-month AV Registry Data. […]

Contego Medical Completes Enrollment of the PERFORMANCE II Carotid Stent Trial

RALEIGH, N.C., Nov. 14, 2022 /PRNewswire/ — Contego Medical, Inc. announced that enrollment of the PERFORMANCE II clinical trial has been completed. PERFORMANCE II is designed to evaluate the safety and effectiveness of the Neuroguard IEP® 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection. The Neuroguard IEP System is […]

New Ultra-Compact SONIMAGE MX1 Platinum Redefines Image Quality in Point-of-Care Ultrasound at RSNA 2022

WAYNE, N.J, Nov. 14, 2022 (GLOBE NEWSWIRE) — Konica Minolta Healthcare Americas, Inc., a leader in medical diagnostic imaging and healthcare information technology, introduces its next-generation, compact point-of-care ultrasound system (POCUS), SONIMAGE® MX1 Platinum, delivering incredible detail resolution for superior image quality. Clinicians can hand carry the SONIMAGE MX1 Platinum System wherever it […]

Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results

Ongoing INOpulse® REBUILD Phase 3 trial enrollment completion expected in the first quarter of 2023, with pivotal top-line data readout anticipated in the third quarter of 2023 WARREN, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on […]

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical […]

Aerovate Therapeutics Announces Third Quarter 2022 Financial Results

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2022, and recent business highlights. Recent Highlights Progress Continued […]

Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates

WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today reported financial results for the third quarter ended September 30, 2022 and provided key business updates. “The Company had several notable deliverables this quarter […]